Compare Cart
Cover Image
Market Research Report
Product code 
850121

Asia-Pacific Insulin Infusion Pumps Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
Published: | Mordor Intelligence Pvt Ltd | 90 Pages | Delivery time: 2-3 business days

Price

Back to Top
Asia-Pacific Insulin Infusion Pumps Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
Published: January 17, 2022
Mordor Intelligence Pvt Ltd
Content info: 90 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents

Key Highlights

  • The Asia-Pacific insulin infusion pumps market is expected to witness a CAGR of 6%, during the forecast period (2019-2024), due to the exponentially increasing diabetes population in the Asian region.
  • Patients with type-1 diabetes mostly use the insulin infusion pump. However, companies are also targeting patients with type-2 diabetes, in order to provide better healthcare facility and expand the market. Insulin pump reduces the burden of multiple daily injections. The diabetes epidemic in the Asia-Pacific region offers significant unmet needs and market opportunities.

Key Market Trends

Increasing Diabetic Population

  • Over the past few decades, Asian countries have witnessed an epidemic increase in diabetic patients. More than 60% of the diabetic population exists in developing countries.
  • Self-monitoring of blood glucose fails to monitor blood sugar level from time to time. Thus, there is a need for continuous glucose monitoring, along with an insulin pump for diabetes patients.

China Accounts for the Highest Market Share in the Asia-Pacific Region

  • In the Asia-Pacific insulin infusion pumps market, China accounted for close to 72% of the market value, in 2018. By 2024, the insulin infusion pump market in China is likely to be valued at USD 0.9 billion.
  • Malaysia and Vietnam account for the highest CAGR of 7% and 6%, respectively, in the market studied.

Competitive Landscape

  • Medtronic is the market leader, and is expected to maintain its position during the forecast period.
  • January 2018: Medtronic, a medical device company, plans to open the operation site in China, to cater to the diabetes epidemic in the country.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Product Code: 65402

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product (Value and Volume, 2012-2024)
    • 5.1.1 Insulin Pump
    • 5.1.2 Infusion Set
    • 5.1.3 Reservoir
  • 5.2 By Geography
    • 5.2.1 Asia-Pacific
      • 5.2.1.1 Japan (Value and Volume, 2012-2024)
      • 5.2.1.1.1 By Insulin Pump Device
      • 5.2.1.1.2 By Infusion Set
      • 5.2.1.1.3 By Reservoir
      • 5.2.1.2 South Korea (Value and Volume, 2012-2024)
      • 5.2.1.2.1 By Insulin Pump Device
      • 5.2.1.2.2 By Infusion Set
      • 5.2.1.2.3 By Reservoir
      • 5.2.1.3 China (Value and Volume, 2012-2024)
      • 5.2.1.3.1 By Insulin Pump Device
      • 5.2.1.3.2 By Infusion Set
      • 5.2.1.3.3 By Reservoir
      • 5.2.1.4 India (Value and Volume, 2012-2024)
      • 5.2.1.4.1 By Insulin Pump Device
      • 5.2.1.4.2 By Infusion Set
      • 5.2.1.4.3 By Reservoir
      • 5.2.1.5 Australia (Value and Volume, 2012-2024)
      • 5.2.1.5.1 By Insulin Pump Device
      • 5.2.1.5.2 By Infusion Set
      • 5.2.1.5.3 By Reservoir
      • 5.2.1.6 Vietnam (Value and Volume, 2012-2024)
      • 5.2.1.6.1 By Insulin Pump Device
      • 5.2.1.6.2 By Infusion Set
      • 5.2.1.6.3 By Reservoir
      • 5.2.1.7 Malaysia (Value and Volume, 2012-2024)
      • 5.2.1.7.1 By Insulin Pump Device
      • 5.2.1.7.2 By Infusion Set
      • 5.2.1.7.3 By Reservoir
      • 5.2.1.8 Indonesia (Value and Volume, 2012-2024)
      • 5.2.1.8.1 By Insulin Pump Device
      • 5.2.1.8.2 By Infusion Set
      • 5.2.1.8.3 By Reservoir
      • 5.2.1.9 Philippines (Value and Volume, 2012-2024)
      • 5.2.1.9.1 By Insulin Pump Device
      • 5.2.1.9.2 By Infusion Set
      • 5.2.1.9.3 By Reservoir
      • 5.2.1.10 Thailand (Value and Volume, 2012-2024)
      • 5.2.1.10.1 By Insulin Pump Device
      • 5.2.1.10.2 By Infusion Set
      • 5.2.1.10.3 By Reservoir
      • 5.2.1.11 Rest of Asia-Pacific (Value and Volume, 2012-2024)
      • 5.2.1.11.1 By Insulin Pump Device
      • 5.2.1.11.2 By Infusion Set
      • 5.2.1.11.3 By Reservoir

6 MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population (2012-2024)
  • 6.2 Type-2 Diabetes Population (2012-2024)

7 COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Medtronic
    • 7.1.2 Insulet
    • 7.1.3 Roche
    • 7.1.4 Animas
    • 7.1.5 Tandem
    • 7.1.6 Ypsomed
    • 7.1.7 Cellnovo
  • 7.2 COMPANY SHARE ANALYSIS
    • 7.2.1 Roche
    • 7.2.2 Animas
    • 7.2.3 Medtronic
    • 7.2.4 Others

8 MARKET OPPORTUNITES AND FUTURE TRENDS